Solventum's (SOLV) largest shareholder Trian Fund Management said Wednesday that the company's separation from 3M (MMM) should have enable significant improvements, but is not living up to the potential.
Solventum performance has declined since the spinoff and is barely growing at low-20% operating margin despite a favorable core market backdrop, Trian said in an open letter to Solventum shareholders.
Solventum must outline a long-term plan to restore its historical growth and profitability, Trian added. Trian holds roughly 5% stake in Solventum.
Solventum can also benefit from simplifying its portfolio, focusing on core medical-surgical segment, and capitalizing on divestiture opportunities.
Solventum shares were down 1% in recent trading.
Price: 68.56, Change: -0.85, Percent Change: -1.22
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。